AbbVie Inc.

AbbVie Inc.

266.70
EUR
-3.70
(-1.37%)
5.15EPS
45.09P/E
411.48BMarket Cap
Feb 03Next Earn

Total Valuation

EUR

As of September 30, 2026, AbbVie, Inc. carries a market capitalization of 411.48B, placing it among publicly traded companies globally. Its enterprise value stands at 473.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap411.48B
Enterprise Value473.39B

Important Dates

AbbVie, Inc.'s next confirmed earnings release is scheduled for February 3, 2027.

Earnings Date2/3/2027

Share Statistics

As of September 30, 2026, AbbVie, Inc. has 1.77B shares outstanding.

Shares Outstanding1.77B

Valuation Ratios

As of September 30, 2026, AbbVie, Inc. trades at a trailing price-to-earnings ratio of 45.09. The price-to-sales ratio is 7.06, and the price-to-book ratio stands at -101.76.

PE Ratio45.09
PS Ratio7.06
PB Ratio-101.76
P/TBV Ratio-4.71
P/FCF Ratio24.79
P/OCF Ratio23.21

Enterprise Valuation

As of September 30, 2026, AbbVie, Inc. trades at an EV/EBITDA multiple of 18.57 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.27 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AbbVie, Inc. trades at an EV/FCF ratio of 25.22, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 473.39B versus a market cap of 411.48B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales8.13
EV / EBITDA18.57
EV / EBIT25.27
EV / FCF25.22

Financial Position

As of September 30, 2026, AbbVie, Inc. maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,782.79, indicating conservative leverage, while an interest coverage ratio of 9.70 demonstrates adequate ability to service its debt obligations.

Current Ratio0.87
Quick Ratio0.56
Debt / Equity-1,782.79
Debt / EBITDA2.80
Interest Coverage9.70

Financial Efficiency

EUR

These figures cover the twelve months ended September 30, 2026. Return on invested capital (ROIC) comes in at 24.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.88, useful for judging operating efficiency across full business cycles. The company generates approximately 1.02M in revenue per employee across its workforce of 57,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.39 indicates how many times AbbVie, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)7.35
Return on Invested Capital (ROIC)24.06
Return on Capital Employed (ROCE)17.88
Revenue Per Employee1.02M
Employee Count57,000.00
Inventory Turnover3.39

Taxes

EUR

Over the twelve months ended September 30, 2026, AbbVie, Inc. recorded 2.18B in income tax expense. That works out to an effective tax rate of 19.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 11.31B, leaving 9.12B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax2.18B
Effective Tax Rate19.24

Stock Price Statistics

EUR

As of the close on November 17, 2026, AbbVie, Inc.'s stock has gained approximately 32.36% over the past 52 weeks. The 50-day moving average sits at 244.47, while the 200-day moving average is 209.79.

52-Week Price Change32.36%
50-Day Moving Average244.47
200-Day Moving Average209.79

Income Statement

EUR

Over the twelve months ended September 30, 2026, AbbVie, Inc. generated 58.24B in revenue and converted that into 9.12B in net income, yielding earnings per share of 5.15. EBITDA reached 25.50B, while operating income came in at 20.95B.

Revenue58.24B
Gross Profit42.94B
Operating Income20.95B
Pretax Income11.31B
Net Income9.12B
EBITDA25.50B
EBIT18.73B
Earnings Per Share (EPS)5.15

Balance Sheet

EUR

As of September 30, 2026, AbbVie, Inc. holds 9.51B in cash and equivalents against 71.38B in total debt, resulting in a net debt position of 61.87B. Total book value stands at -4.04B, with working capital of -4.96B providing operational flexibility.

Cash & Cash Equivalents9.51B
Total Debt71.38B
Net Debt61.87B
Equity (Book Value)-4.04B
Book Value Per Share-2.29
Working Capital-4.96B

Cash Flow

EUR

AbbVie, Inc. produced 17.72B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.07B in capital expenditures, free cash flow totaled 16.65B - equivalent to 9.42 per share.

Operating Cash Flow17.72B
Capital Expenditures-1.07B
Free Cash Flow16.65B
FCF Per Share9.42

Margins

Over the twelve months ended September 30, 2026, AbbVie, Inc. posted a gross margin of 73.72, reflecting its pricing power and cost economics. The operating margin of 35.98 and net profit margin of 15.67 provide insight into operational efficiency.

Gross Margin73.72
Operating Margin35.98
Pretax Margin19.41
Profit Margin15.67
EBITDA Margin43.78

Dividends & Yields

EUR

Over the twelve months ended September 30, 2026, AbbVie, Inc. paid dividends of 6.06 per share. The dividend payout ratio of 117.23 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.03, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.32, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AbbVie, Inc. shareholders.

Dividend Per Share6.06
Payout Ratio117.23
Shareholder Yield0.32
FCF Yield4.03

Scores

As of September 30, 2026, AbbVie, Inc. has an Altman Z-Score of 4.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.00